NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Early Detection of Biliary Atresia Using a Practical Clinical Pathway
Biliary atresia (BA) is a rare infant liver disease where early diagnosis improves outcomes. A Texas center proposes pairing direct/conjugated bilirubin testing with a feeding ultrasound to identify infants needing urgent evaluation, potentially reducing delays and invasive procedures.
Biliary atresia (BA) is a rare liver disease in infants where bile ducts are malformed, causing bile buildup and progressive liver injury. Early treatment (Kasai portoenterostomy) before 30-45 days of life offers the best chance to delay or avoid liver transplantation, but diagnosis is often delayed beyond 60 days.
The pathway combines two steps: (1) measuring direct or conjugated bilirubin (DB/Bc) in newborns and early outpatient visits, and (2) performing a feeding abdominal ultrasound exam for infants with high DB/Bc levels. The ultrasound looks for an absent duct at the hilum (DaH) or maximum echogenicity (MxE) >4.0 mm, which raises concern for BA.
Instead of requiring fasting, the infant feeds before or during imaging, which can make the duct at the hilum easier to visualize. The exam also measures maximum echogenicity near the right portal vein.
The pathway involves the full care team: nursery providers, primary care physicians (PCPs), radiologists, hepatologists, and surgeons. The goal is to give clinicians clearer signals at critical time points.
DB/Bc measurements are recommended in the newborn nursery and early outpatient visits. Specifically, at 2-4 weeks for infants with persistent jaundice, pale stools, or a previous high DB/Bc result, consistent with AAP guidance.
Universal newborn DB/Bc screening could reduce delays and address disparities by identifying risk before visual signs (like jaundice or pale stools) are missed or misread.
If MxE >4.0 mm or absent DaH is found, it raises concern for BA and may prompt definitive evaluation (e.g., liver biopsy or cholangiogram). Other findings may support continued outpatient assessment.
The pathway was developed at Texas Children's Hospital and Baylor College of Medicine, with collaborators from Stanford University. It was published in the World Journal of Pediatric Surgery on March 16, 2026.